Speaker(s): 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe the prevalence, genetic architecture, and clinical impact of monogenic familial hypercholesterolemia (FH) across African and European ancestry populations, including differences in pathogenic variants and variants of uncertain significance (VUS).
2. Interpret the effects of pathogenic and VUS variants in FH-related genes on LDL-C levels and atherosclerotic cardiovascular disease risk, with attention to ancestry-specific differences and implications for underdiagnosis and risk stratification.
3. Evaluate the role of albumin biology—including rare ALB loss-of-function variants and polygenic albumin risk—in modulating LDL cholesterol, and compare these mechanisms to classic LDL receptor–mediated pathways to inform clinical assessment and management of hypercholesterolemia.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Candice Laubach, MBA, Christa Martin, PhD, Jennifer Nunamaker, Christian Lynch, MPH, Adam Buchanan, MS, MPH, CGC, and David Rolston, MD, FACP have no identified disclosures. 

The Planning Committee member consisting of Eric Wright, PharmD, MPH has identified disclosures: Consultant/Advisor with AstraZeneca.

Content Disclosure: 

This presentation/content is HIPAA compliant. 

None